was published in the **Federal Register** on April 9, 2025, FR Doc 2025–06088, 90 FR 15256.

This meeting notice is to cancel the meeting scheduled June 18, 2025. This meeting will not be rescheduled.

Dated: April 11, 2025.

David W. Freeman,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–06486 Filed 4–16–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; FFRDC Review Meeting.

Date: May 9, 2025.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate contract proposals.

Address: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W530, Rockville, Maryland 20850.

Meeting Format: Virtual Meeting.

Contact Person: Shamala K. Srinivas, Ph.D., Associate Director, Office of Referral, Review, and Program Coordination, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W530, Rockville, Maryland 20850, 240–276–6442, *ss537t@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: April 11, 2025.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–06556 Filed 4–16–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Minority Health and Health Disparities; Amended Notice of Partially Closed Meeting

Notice is hereby given of a change in the meeting of the National Advisory Council on Minority Health and Health Disparities, May 06, 2025, 10:00 a.m. to May 06, 2025, 05:30 p.m., National Institutes of Health, 31 Center Drive, Bethesda, MD 20892 which was published in the **Federal Register** on March 31, 2025, FR Doc 2025–05511, 90 FR 14270.

This meeting notice is being amended to change the meeting format from hybrid to virtual. The meeting is partially Closed to the public.

Dated: April 11, 2025.

David W. Freeman,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–06488 Filed 4–16–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Conductive Polymer Coated Electrodes for Dielectrophoretic Cell Positioning and Electroporation

AGENCY: National Institutes of Health, National Institute of Allergy and Infectious Diseases.

ACTION: Notice.

SUMMARY: The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Cambridge Enterprise Limited, University of Cambridge, located in Cambridge, United Kingdom, to practice the inventions embodied in the patent applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice.

DATES: Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases on or before May 2, 2025 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Wade Green, Ph.D., Acting Branch Chief, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Suite 2G, MSC9804, Rockville, MD 20852–9804, phone number 301–761–7505, or *wade.green@nih.gov.*

SUPPLEMENTARY INFORMATION: The following represents the intellectual property to be licensed under the prospective agreement: European Patent Application Patent Application No. EP23386021.2, filed March 10, 2023, titled ''Conductive Polymer Coated Electrodes for Dielectrophoretic Cell Positioning and Electroporation'' (HHS Reference No. E–266–2023–0–EP–01) and International Patent Application No. PCT/EP2024/056247, filed on March 8, 2024, titled ''Conductive Polymer Coated Electrodes for Dielectrophoretic Cell Positioning and Electroporation'' (HHS Reference No. E–266–2023–0–PC–01). All rights in these inventions have been assigned to Cambridge Enterprise Limited and the Government of the United States of America.

The prospective patent license will be for the purpose of consolidating patent rights with Cambridge Enterprise Limited, the co-owner of said rights, for commercial development and marketing. Consolidation of these co-owned rights is intended to expedite development of the invention, consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C. 200–212.

The prospective patent license will be exclusive, and may be limited to those fields of use commensurate in scope with the patent rights. It will be sublicensable, and any sublicenses granted by Cambridge Enterprise Limited in the United Kingdom will be subject to the provisions of 37 CFR part 404.

The subject patent rights pertain to devices and methods for single-cell electroporation of human cells for clinical uses. Specifically, this subject invention describes certain conductive polymer electrodes that have properties that may allow for their use in the development of microfluidic-based electroporation devices for clinical uses.